1089 Antipruritic effect of the novel kappa opioid receptor agonist CR845

Patients with chronic kidney disease are commonly afflicted by pruritus, a condition with no treatment approved in the USA. The etiology of this condition is likely multifactorial, including systemic inflammation and deficiency in the endogenous kappa opioid system. CR845 is a novel and full kappa opioid receptor agonist with no off-target activities, including mu- or delta-opioid receptors. In addition to its unique receptor profile, the peptidic structure of CR845 restricts its entry into the central nervous system.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Pharmacology and Drug Development Source Type: research